SGLT2 Inhibitors and Cognitive Impairment in Type 2 Diabetes
Author Information
Author(s): Zhang Yibin, Liao Xiaobin, Xu Jialu, Yin Jiaxin, Li Shan, Li Mengni, Shi Xiaoli, Zhang Shujun, Li Chunyu, Xu Weijie, Yu Xuefeng, Yang Yan
Primary Institution: Tongji Medical College, Huazhong University of Science and Technology
Hypothesis
Can sodium–glucose cotransporter 2 inhibitors (SGLT2i) prevent or treat cognitive impairment in patients with type 2 diabetes?
Conclusion
SGLT2 inhibitors may help improve cognitive function and reduce the risk of dementia in patients with type 2 diabetes.
Supporting Evidence
- SGLT2 inhibitors have shown potential benefits in preventing cognitive decline in diabetic patients.
- Clinical trials indicate that SGLT2 inhibitors may reduce the risk of dementia.
- Meta-analyses suggest SGLT2 inhibitors improve cognitive function scores in patients with type 2 diabetes.
- Empagliflozin and dapagliflozin have been associated with lower dementia mortality rates.
- Studies indicate that SGLT2 inhibitors may have unique protective effects against vascular cognitive impairment.
Takeaway
SGLT2 inhibitors are medicines that help people with diabetes and might also make their brains work better.
Methodology
This review compiles mechanisms and clinical evidence from various studies and meta-analyses.
Potential Biases
Potential biases may arise from the variability in study populations and methodologies.
Limitations
The evidence from clinical trials is mixed, with some studies showing significant results and others not.
Participant Demographics
The studies included participants with type 2 diabetes, primarily older adults.
Statistical Information
P-Value
0.019
Confidence Interval
95%CI −0.043 to −0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website